INCB3344

• CAT Number: I001055
• CAS Number: 1262238-11-8
• Molecular Formula: C29H34F3N3O6
• Molecular Weight: 577.24
• Purity: ≥95%
• Synonyms: N-[2-[[(3S,4S)-1-[4-(1,3-benzodioxol-5-yl)-4-hydroxycyclohexyl]-4-ethoxypyrrolidin-3-yl]amino]-2-oxoethyl]-3-(trifluoromethyl)benzamide
• Target: Immunology/Inflammation
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• IC50: 10 nM [1]
• InChI: InChI=1S/C29H34F3N3O6/c1-2-39-25-16-35(21-8-10-28(38,11-9-21)19-6-7-23-24(13-19)41-17-40-23)15-22(25)34-26(36)14-33-27(37)18-4-3-5-20(12-18)29(30,31)32/h3-7,12-13,21-22,25,38H,2,8-11,14-17H2,1H3,(H,33,37)(H,34,36)/t21?,22-,25-,28?/m0/s1
• InChIKey: MZEOSVPWMSEFPW-XYCDVDSTSA-N
• SMILES: CCO[C@H]1CN(C[C@@H]1NC(=O)CNC(=O)C2=CC(=CC=C2)C(F)(F)F)C3CCC(CC3)(C4=CC5=C(C=C4)OCO5)O

INCB3344(CAT: I001055) is a novel, potent, and selective small molecule antagonist targeting the mouse CCR2 receptor. It effectively inhibits the binding of CCL2 (monocyte chemoattractant protein-1) to CCR2 on monocytes with nanomolar potency. By blocking this chemokine-receptor interaction, INCB3344 disrupts monocyte recruitment to sites of inflammation, making it a valuable tool in inflammation and immunology research. It is particularly useful for studying the role of the CCR2/CCL2 axis in inflammatory diseases, including atherosclerosis, autoimmune disorders, and cancer. INCB3344 provides insights into therapeutic strategies for modulating immune cell trafficking and resolving chronic inflammatory conditions.